prodrugs are bioreversible derivatives of drug molecules that undergo
intermolecular or intramolecular reactions by enzymatic or chemical
biotransformation in the human body to give the corresponding active
parent drugs and a non-toxic promoiety. Prodrugs have been
extensively and successfully used as a chemical tool for modification
of the physicochemical, pharmacokinetic as well as pharmacodynamic
characteristics of commonly used drugs and new drugs.This mini
review focuses on the design, synthesis and pharmacological effects of
several prodrugs and codrugs of the non-steroidal anti-inflammatory
(NSAIDs), mefenamic acid. Exploitation of the prodrug approach has
the potential to achieve a reduction of mefenamic acid GI (gastrointestinal)
intolerance, enhance its bioavailability, mask its unpleasant
sensation and prolong its duration of action. In addition, utilizing the prodrug concept migh
enhance the bioavailability of the counter partner drug of mefenamic acid codrug by
increasing its lipophilicity.